Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation

ONAT, A.; Can, Günay; HERGENC, G.; YAZICI, M.; KARABULUT, A.; ALBAYRAK, S.

doi:10.1038/sj.ijo.0803552

Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation

ONAT A., Can G., HERGENC G., YAZICI M., KARABULUT A., ALBAYRAK S.

INTERNATIONAL JOURNAL OF OBESITY, vol.31, no.7, pp.1119-1125, 2007 (SCI-Expanded)

Publication Type: Article / Article
Volume: 31 Issue: 7
Publication Date: 2007
Doi Number: 10.1038/sj.ijo.0803552
Journal Name: INTERNATIONAL JOURNAL OF OBESITY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.1119-1125
Istanbul University Affiliated: No

Abstract

Objectives: To investigate the role of serum apolipoprotein (apo) B levels in predicting metabolic syndrome (MS), hypertension, atherogenic dyslipidemia and type II diabetes.